Repository logo
 
Publication

Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound

dc.contributor.authorSilva, Ana Catarina
dc.contributor.authorGonzález-Mira, E.
dc.contributor.authorGarcía, M.L.
dc.contributor.authorEgea, M.A.
dc.contributor.authorFonseca, J.
dc.contributor.authorSilva, R.
dc.contributor.authorSantos, D.
dc.contributor.authorSouto, Eliana B.
dc.contributor.authorFerreira, D.
dc.date.accessioned2021-05-06T09:22:10Z
dc.date.available2021-05-06T09:22:10Z
dc.date.issued2011
dc.description.abstractThe suitability of solid lipid nanoparticles (SLN) for the encapsulation of risperidone (RISP), an antipsychotic lipophilic drug, was assessed for oral administration. The hot high pressure homogenization (HPH) and the ultrasound (US) technique were used as production methods for SLN. All the studies on the SLN formulations were done in parallel, in order to compare the results and conclude about the advantages and limitations of both techniques. The particle sizes were in the nanometer range for all prepared SLN formulations and the zeta potential absolute values were high, predicting good long-term stability. Optical analyses demonstrated the achievement of stable colloidal dispersions. Physicochemical characterization of dispersions and bulk lipids, performed by differential scanning calorimetry (DSC) and X-ray assays, support prediction of occurrence of drug incorporation in the SLN and good long term stability of the systems. The toxicity of SLN with Caco-2 cells and the existence of contaminations derived from the production equipments were assessed by the (4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) assay. The results showed 90% of cell viability after SLN exposure, with no significant differences within all prepared formulations (p > 0.05). From this study, we conclude that SLN can be considered as efficient carriers for RISP encapsulation. Moreover, HPH and US revealed to be both effective methods for SLN production.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1016/j.colsurfb.2011.03.035pt_PT
dc.identifier.issn0927-7765
dc.identifier.urihttp://hdl.handle.net/10284/9891
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectSolid lipid nanoparticlespt_PT
dc.subjectOral deliverypt_PT
dc.subjectRisperidonept_PT
dc.subjectHigh pressure homogenizationpt_PT
dc.subjectUltrasoundpt_PT
dc.subjectBiocompatibilitypt_PT
dc.titlePreparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasoundpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage165pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage158pt_PT
oaire.citation.titleColloids and Surfaces B: Biointerfacespt_PT
oaire.citation.volume86pt_PT
person.familyNameSilva
person.familyNameSouto
person.givenNameAna Catarina
person.givenNameEliana B.
person.identifier953153
person.identifier.ciencia-id5C1D-ED22-0D64
person.identifier.ciencia-id8D1B-21CC-90F7
person.identifier.orcid0000-0001-6923-0232
person.identifier.orcid0000-0002-9737-6017
person.identifier.ridF-1875-2017
person.identifier.ridL-9813-2014
person.identifier.scopus-author-id57028697500
person.identifier.scopus-author-id8839435500
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication67e7f707-32ec-444a-a20d-a17f8e6e7c21
relation.isAuthorOfPublicationb9f031fa-7f68-4196-b9c6-9f17cd542f12
relation.isAuthorOfPublication.latestForDiscoveryb9f031fa-7f68-4196-b9c6-9f17cd542f12

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
COLSUB_2011_Preparation, characterization and biocompatibility studies on risperidone-loaded US vs HPH.pdf
Size:
1.18 MB
Format:
Adobe Portable Document Format